Literature DB >> 27032454

Transradial access for visceral endovascular interventions in morbidly obese patients: safety and feasibility.

Derek M Biederman1, Brett Marinelli1, Paul J O'Connor1, Joseph J Titano1, Rahul S Patel1, Edward Kim1, Nora E Tabori1, Francis S Nowakowski1, Robert A Lookstein1, Aaron M Fischman1.   

Abstract

PURPOSE: Transradial access (TRA) has been shown to lower morbidity and bleeding complications compared to transfemoral access in percutaneous coronary interventions. Morbid obesity, commonly defined as a body mass index (BMI) ≥40 kg/m2, has been shown to be a risk factor for access site complications irrespective of access site. This study evaluates the safety and feasibility of performing visceral endovascular interventions in morbidly obese patients via TRA.
METHODS: Procedural details, technical success, and 30-day major and minor access site, bleeding, and neurological adverse events were prospectively recorded in a database of 1057 procedures performed via the radial artery. From this database we identified 22 visceral interventions performed with TRA in 17 morbidly obese patients (age: 53 ± 11 years, female: 71%) with a median BMI of 42.7 kg/m2.
RESULTS: Interventions included radio-embolization (n = 7, 31.8%), chemo-embolization (n = 6, 27.3%), uterine fibroid embolization (n = 4, 18.2%), renal embolization (n = 2, 9.1%), hepatic embolization (n = 1, 4.5%), lumbar artery embolization (n = 1, 4.5%), and renal angioplasty (n = 1, 4.5%). The technical success was 100%. There were no major or minor adverse access site, bleeding, or neurological complications at 30 days.
CONCLUSIONS: This study suggests visceral endovascular interventions performed in morbidly obese patients are safe and feasible.

Entities:  

Mesh:

Year:  2016        PMID: 27032454     DOI: 10.5301/jva.5000530

Source DB:  PubMed          Journal:  J Vasc Access        ISSN: 1129-7298            Impact factor:   2.283


  6 in total

1.  Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year.

Authors:  Clifford R Weiss; Godwin O Abiola; Aaron M Fischman; Lawrence J Cheskin; Jay Vairavamurthy; Brian P Holly; Olaguoke Akinwande; Franklin Nwoke; Kalyan Paudel; Stephen Belmustakov; Kelvin Hong; Rahul S Patel; Eun J Shin; Kimberley E Steele; Timothy H Moran; Richard E Thompson; Taylor Dunklin; Harvey Ziessman; Dara L Kraitchman; Aravind Arepally
Journal:  Radiology       Date:  2019-04-02       Impact factor: 11.105

2.  Prone transradial catheterization for combined single-session endovascular and percutaneous interventions: approach, technical success, safety, and outcomes in 15 patients.

Authors:  Rajiv N Srinivasa; Jeffrey Forris Beecham Chick; Joseph J Gemmete; Bill S Majdalany; Anthony Hage; Alex Jo; Ravi N Srinivasa
Journal:  Diagn Interv Radiol       Date:  2018-09       Impact factor: 2.630

Review 3.  Transradial approach and its variations for neurointerventional procedures: Literature review.

Authors:  Luis Alberto Domitrovic Zalocar; Gustavo Doroszuk; Javier Goland
Journal:  Surg Neurol Int       Date:  2020-08-15

4.  Non-target digital ischemia in an ulnar artery distribution following transradial access: Case report and review of best practice techniques.

Authors:  Patrick Kennedy; Darren Klass; John Chung
Journal:  J Vasc Access       Date:  2021-03-14       Impact factor: 2.326

Review 5.  Transradial Embolization, an Underused Type of Uterine Artery Embolization Approach: A Systematic Review.

Authors:  Loredana Maria Maria Himiniuc; Mara Murarasu; Bogdan Toma; Razvan Popovici; Ana-Maria Grigore; Ioana-Sadiye Scripcariu; Mihaela Oancea; Mihaela Grigore
Journal:  Medicina (Kaunas)       Date:  2021-01-20       Impact factor: 2.430

6.  Nonfemoral Arterial Hemostasis Following Percutaneous Intervention Using a Focused Compression Device.

Authors:  Louis-Xavier Barrette; Ansar Z Vance; Susan Shamimi-Noori; Gregory P Nadolski; Shilpa Reddy; Kathleen M Kratz; Jonas W Redmond; Timothy W I Clark
Journal:  Cardiovasc Intervent Radiol       Date:  2020-02-10       Impact factor: 2.740

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.